C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
C-Tech Analytical Solutions
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!
Get a free Nalgene bottle when you send us an enquiry!

Pharma Press Releases

Keep up to date with the latest technological developments happening across the Pharmaceutical industry. Our press releases can help you boost your online reach and exposure worldwide. Our Press releases provides information on the latest research in pharma.

ImmixBio Announces FDA Orphan Drug Designation for IMX-110 for the Treatment of Soft Tissue Sarcoma

Thursday, September 30, 2021

Immix Biopharma Inc a biotechnology company pioneering Tissue Specific Therapeutics TSTxTM for oncology and inflammation today announced that the US Food and Drug Administration FDA has granted orphan drug designation ODD to IMX for the treatment of...

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status

Thursday, September 30, 2021

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease announced today the launch of an enhanced version of...

Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals

Thursday, September 30, 2021

Takeda Pharmaceutical Company Limited and JCR Pharmaceuticals Co Ltd announced a geographicallyfocused exclusive collaboration and license agreement to commercialize JR INN pabinafusp alfa an investigational nextgeneration recombinant fusion protein...

Prime Therapeutics and Pear Therapeutics announce first comprehensive value-based agreement for prescription digital therapeutics reSET® and reSET-O®

Wednesday, September 29, 2021

More than million Americans struggle with drug addiction while only receive treatment Prime Therapeutics LLC Prime and Pear Therapeutics Inc Pear have developed a comprehensive valuebased agreement for prescription digital therapeutics PDTs This va...

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older

Wednesday, September 29, 2021

Mirum Pharmaceuticals Inc a leader in rare liver disease today announced that the US Food and Drug Administration FDA has approved LIVMARLI maralixibat oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome ALGS on...

FDA Approves Abbott's Amplatzer™ Talisman™ System for PFO Closure in People at Risk of Recurrent Stroke

Wednesday, September 29, 2021

Abbott today announced that the US Food and Drug Administration FDA has approved the companys Amplatzer Talisman PFO Occlusion System to treat people with a patent foramen ovale PFO a small opening between the upper chambers of the heart who are at...

Lantern Pharma Enters into Strategic Collaboration with Deep Lens -- Partnership Expected to Accelerate Enrollment in Upcoming Phase 2 Clinical Trial

Tuesday, September 28, 2021

Lantern Pharma a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence AI platform to transform the cost pace and timeline of oncology drug discovery and development and Deep Lens a digital healthcare company foc...

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine

Tuesday, September 28, 2021

AbbVie announced that the US Food and Drug Administration FDA approved QULIPTA atogepant for the preventive treatment of episodic migraine in adults QULIPTA is the first and only oral calcitonin generelated peptide CGRP receptor antagonist gepant spe...

FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency

Tuesday, September 28, 2021

Catalyst Biosciences Inc announced that the US Food and Drug Administration FDA has granted Orphan Drug Disease Designation ODD for its lead product candidate subcutaneous Marzeptacog alfa activated or MarzAA for the treatment of Factor VII Deficienc...

Chemomab Therapeutics Announces Collaboration with Leeds University to Further Elucidate the Role of CCL24 in Vascular Damage Associated with Systemic Sclerosis

Monday, September 27, 2021

Chemomab Therapeutics Ltd a clinicalstage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need today announced a research collaboration with Leeds University t...